Will big pharma buy back into medtech?
This article was originally published in Clinica
Over the last few years, pharmaceutical companies have been divesting non-core assets as they free up much needed cash to make investments that support their core business needs.
You may also be interested in...
Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.
Nano-X Imaging is on a mission to disrupt the market for X-ray imaging equipment by offering a low-cost medical imaging service to untapped markets through a network of equipment dotted around the world. However, some shareholders are claiming the company mislead investors.